Thesis
Two NDAs at FDA simultaneously, both past mid-cycle with no major concerns flagged — approval of either or both validates Praxis's precision epilepsy engine
Praxis enters late 2026 with two NDAs simultaneously under active FDA review, relutrigine for a devastating childhood epilepsy with no approved therapy and ulixacaltamide for essential tremor, both past mid-cycle with clean safety and efficacy signals. The thesis resolves on whether one or both drugs earn approval, converting $1.4 billion in cash and a commercial infrastructure already being built into a self-sustaining rare-disease franchise. The primary approval risk for relutrigine is the single-arm-adjacent sensitivity-analysis extension that triggered a three-month PDUFA delay, raising the question of whether existing efficacy data withstand FDA's full statistical scrutiny.
Focus
Relutrigine NDA PDUFA decision for SCN2A and SCN8A DEE
2026-12-27
Bull
FDA approves relutrigine on or before the December 27, 2026 PDUFA date, making it the first therapy approved for SCN2A and SCN8A developmental and epileptic encephalopathy. Approval would unlock a Pediatric Review Voucher, validate the precision genotype-guided approach across the broader pipeline, and trigger the commercial launch for which field force hiring and infrastructure build-out are already underway — compressing the time-to-revenue timeline and de-risking the simultaneous ulixacaltamide NDA.
Bear
The most likely failure mode is a Complete Response Letter stemming from the three-month PDUFA extension, which was triggered by submission of additional sensitivity analyses — suggesting FDA has residual questions about the robustness of efficacy data in this small, genetically defined patient population. A second failure mode is a label narrower than both SCN2A and SCN8A (e.g., restricting to one genotype), which would materially reduce the addressable market and partially undermine the precision epilepsy platform narrative.
Unlock the full thesis for PRAX.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.